Sign up
Pharma Capital

Medexus Pharmaceuticals will begin selling Treosulfan in Canada, and will soon look to the US

Medexus Pharmaceuticals Inc (CVE:MDP) (OTC:PDDPF) CEO Ken d’Entremont tells Proactive Investors that Health Canada has authorized the Montreal-based specialty pharma company to distribute Treosulfan through the special access program.

Treosulfana is a conditioning agent used before stem cell transplantation.

The company will look to bring Treosulfann to the US, according to d'Entremont.


View full MDP profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.